BSA Behavioral Health announced it is expanding its mental health services to include Spravato (esketamine) nasal spray, for ...

Spravato was first approved for use in 2019 to treat people with major depressive disorder who did not respond to at least two other antidepressants.Under that approval, patients had to take an ...

Spravato or other antidepressants may increase the risk of suicidal thoughts or actions. If you or your child is about to harm themselves, call 911 or call or text 988, the Suicide & Crisis Lifeline.

Spravato is used to treat the following forms of depression in adults. It’s unknown how Spravato works to help treat depression. It blocks a certain protein in the brain called N-methyl-D ...

In addition to medication management, I specialize in the administration of Spravato—a prescription nasal spray form of ketamine and the first psychedelic drug to be approved by the FDA for the ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and ...

Johnson & Johnson’s Spravato nasal spray has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA ...

Atai Life Sciences is making incremental progress towards opening door for a first psychedelic treatment for depression. Read ...

Positive study results in Phase 2 lead to a green light for the companies’ combination and plans to move their nasal spray ...

“Spravato's strong sales trajectory supports the notion psychedelics can become commercially viable for mental health,” wrote Jefferies analyst Andrew Tsai in a client note Wednesday.